Genetic Polymorphism of SUMO-Specific Cysteine Proteases − SENP1 and SENP2 in Breast Cancer by unknown
ORIGINAL ARTICLE
Genetic Polymorphism of SUMO-Specific Cysteine
Proteases − SENP1 and SENP2 in Breast Cancer
Alicja Mirecka1 & Zbigniew Morawiec2 & Katarzyna Wozniak1
Received: 14 December 2015 /Accepted: 26 April 2016 /Published online: 13 May 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract SENP proteases take part in post-translational mod-
ification of proteins known as sumoylation. They catalyze
three distinct processes during sumoylation: processing of
SUMO protein, deconjugation of SUMO from the target pro-
tein, and chain editing which mentions to the dismantling of
SUMO chain. Many proteins that are involved in the basic
processes of cells, such as regulation of transcription, DNA
repair or cell cycle control, are sumoylated. The aim of these
studies was to investigate an association between polymorphic
variants (SNPs) of the SENP1 gene (c.1691 + 36C > T,
rs12297820) and SENP2 gene (c.902C > A, p.Thr301Lys,
rs6762208) and a risk of breast cancer occurrence. We per-
formed a case-control study in 324 breast cancer cases and
335 controls using PCR-RLFP. In the case of the SENP1 gene
polymorphism we did not find any association between this
polymorphism and breast cancer risk. In the case of SENP2
gene polymorphism we observed higher risk of breast cancer
for carriers of the A allele (OR =1.33; 95 % CI 1.04–1.69).
Our analysis also showed the genotype C/C (OR =0.67, 95 %
CI 0.48–0.93) and the allele C (OR =0.75, 95%CI 0.59–0.69)
of this polymorphism decrease a risk of breast cancer. We also
checked the distribution of genotypes and frequency of alleles
of the SENP1 and SENP2 genes polymorphisms in groups of
patients with different hormone receptor status, patients with
positive and negative lymph node status and patients with
different tumor grade. Odds ratio analysis showed a higher
risk of metastases in women with the genotype C/C (OR
=2.07, 95 % CI 1.06–4.05) and allele C (OR =2.10 95 % CI
1.10–4.01) of the c.1691 + 36C > T SENP1 gene polymor-
phism. Moreover, we observed reduced risk in women with
the allele T (OR =0.48, 95 % CI 0.25–0.91) in this polymor-
phic site. In the case of SENP2 gene polymorphism we ob-
served that the A/A genotype correlated with the lack of es-
trogen receptor (OR =1.94, 95 % CI 1.04–3.62). Our results
suggest that the variability of the SENP1 and SENP2 genes
may play a role in breast cancer occurrence. Further studies
are needed to clarify their biological functions in breast cancer.
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Introduction
Small ubiquitin-like modifiers (SUMO) conjugation to pro-
teins is a reversible post-translational modification, which
may affect the function, sub-cellular localization and expres-
sion of proteins. Proteins, which are sumoylated take part in
many cellular processes including regulation of transcription,
DNA repair, nuclear transport and cell cycle control.
Mammals express four different SUMO isoforms: SUMO-1,
SUMO-2, SUMO-3 and SUMO-4. However, post-
translational modification of proteins by SUMO-4 is question-
able, as it remains in the inactive form in vivo [1, 2]. SUMO-2
and SUMO-3 share 95-97 % sequence homology and
hence are collectively referred to as SUMO-2/3. SUMO-
2/3 efficiently forms polymeric chains while in contrast
SUMO-1 creates polymeric chains rarely. SUMO modifi-
cation is a highly dynamic process, catalyzed by SUMO-
specific activating (E1), conjugating (E2) and ligating
(E3) enzymes. Sumoylation of target proteins results in
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the formation of isopeptide (amide) bond between the C-
terminal glycine of SUMO and the ε-amino group of ly-
sine within the target proteins [2].
During SUMO metabolism SUMO-specific proteases
(SENPs) catalyze three distinct processes: processing,
deconjugation and chain editing. SUMO proteins are
expressed as precursor proteins that carry a C-terminal exten-
sion of variable length (2–11 amino acids) found after a con-
served di-glycine motif. To function as a modifier of target
proteins, the C-terminal di-glycine motif of the SUMO pro-
teins must be exposed by the action of SUMO specific prote-
ase. SUMO processing activity of SENPs is responsible for
cleavage after the C-terminal di-glycine motif. SUMO
deconjugation activity of SENPs is required for the cleav-
age of amide bond between the C-terminus of the mature
SUMO and the ε-amino group of the target lysine within
the substrates. Chain editing refers to the dismantling of
SUMO chain [3].
Six SUMO-specific SENPs have been identified in
humans, SENPs 1, 2, 3, 5, 6 and 7. There are categorized into
three independent subfamilies: SENP1 and SENP2, SENP3
and SENP5, and SENP6 and SENP7 proteases as the third
subfamily. Unlike endopeptidase activity, all SENP family
members exhibit isopeptidase activity to cleave the isopeptide
bond between the glycine residue of SUMO and the lysine
side chain of the substrate. The catalytic activity is maintained
within a conserved 200 amino acid region in the C-terminal
domain consisting of several highly conserved amino acids
(cysteine, histidine and aspartic acid). SENPs possess a large
N-terminal domain with minimal or no homology to each
other’s domain. It has been suggested that the diversified
N-terminal domains of SENP proteases determine their
substrate specificity by controlling their sub-cellular local-
ization [4]. It was shown that SENP1 localizes to the
nucleoplasm, SENP2 localizes to the nuclear side of the
nuclear pore complex (NPC), SENP3 and SENP5 localize
to the nucleolus, and SENP6 localizes predominantly to
the cytoplasm [4, 5]. Studies also indicate that the non-
covalent binding of SUMO proteases to SUMO protein
through salt bridge is essential for theirs enzymatic activ-
ities - to hydrolyze the C-terminal region of SUMO (hy-
drolase activity) and to remove SUMO from SUMO-
conjugated substrates (isopeptidase activity) [6]. The 6
mammalian SENP enzymes can deconjugate mono-
sumoylated proteins or dissemble polymeric SUMO side
chains. SENP1 and SENP2 can desumoylate cellular sub-
strates that are modified by any of the 3 SUMO isoforms
while the remaining 4 SENPs are more efficient at
deconjugating SUMO-2/3 than SUMO-1 [2].
The expression of several SENPs is altered in numerous
cancers [7]. An elevated SENP1 level was observed in thyroid
oncocytic adenocarcinoma [8], prostate cancer [9–11] and
pancreatic ductal adenocarcinoma (PDAC) [12]. Moreover,
it was shown that SENP1 expression directly correlates with
prostate cancer aggressiveness and recurrence [13]. SENP1
was also over expressed in most of colon cancer tissues.
Results of experiments with siRNA to inhibit SENP1 expres-
sion in DLD-1 colon cancer cell line, suggest a potential role
for SENP1 in colon cancer cell proliferation, tumor formation
and cell cycle progression [14]. SENP2 has been reported to
play a critical role in the control of hepatocellular carcinoma
(HCC) cell growth by modulating the stability of β-catenin
[15]. Moreover, SENP2 functions as a tumor metastasis sup-
pressor in bladder cancer. The effects of SENP2 on bladder
cancer invasion are partially mediated by inhibiting the ex-
pression of MMP13 [16].
According to our knowledge the gene polymorphism
encoding SENP proteases has not been investigated so far in
terms of assessment of breast cancer risk. This fact prompted
us to investigate the correlation between polymorphic variants
(SNPs) of the SENP1 gene (c.1691 + 36C > T, rs12297820)
and SENP2 gene (c.902C > A, p.Thr301Lys, rs6762208) and
breast cancer risk. We also studied an association between the
polymorphisms of the SENP1 and SENP2 genes and clinical
characteristics of breast cancer patients such as lymph node
status, tumor grade, hormone receptors (estrogen and proges-




Blood samples were obtained from 324 women (mean age
60 years) with sporadic breast cancer treated at the
Department of Surgical Oncology, N. Copernicus
Hospital (Lodz, Poland). The clinical characteristic of
breast cancer patients is presented in Table 1. Blood was
collected before surgical treatment and chemotherapy. The
control group (335 women) consisted of age-matched
women who were not diagnosed with cancer and recruited
from Commune Health Clinic in Rzgow and Institute
Polish Mother’s Health Center (Lodz, Poland). The
Local Ethic Committee approved the study and each pa-
tient gave a written consent.
Genomic DNA Isolation
Genomic DNA was prepared from peripheral blood of
breast cancer patients and healthy individuals by using
of commercial AxyPrep™ Blood Genomic DNA
Miniprep Kit (Axygen Biosciences, CA, USA), as rec-
ommended by the manufacturer.
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Selection of Polymorphism and Primers Design
Weobtained a list of SNPs in the SENP1 and SENP2 genes from
the public domain of the National Center for Biotechnology
Information the Single Nucleotide Polymorphisms database
(NCBI dbSNP) at http://www.ncbi.nlm.nih.gov/snp. For this
study we chose the c.1691 + 36C > T (rs12297820) polymor-
phism of the SENP1 gene and the c.902C > A, p.Thr301Lys
(rs6762208) polymorphism of the SENP2 gene. Primers were
designed according to the published nucleotide sequence in
ENSEMBL database and using Primer3Plus software.
Genotype Determination
The restriction fragment length polymorphism reaction (PCR-
RFLP) was used to determine the genotypes of the c.1691 +
36C > T and the c.902C > A polymorphisms of the SENP1
and SENP2 genes, respectively. PCR reaction was performed
in a total reaction volume of 25 μl containing 50 ng of genomic
DNA, 1UBiotools DNApolymerase (Biotools,Madrid, Spain),
1 × reaction buffer (750 mM Tris-HCl (pH 9.0), 500 mM KCl,
200 mM (NH4)2SO4), 0.2 mM of each dNTP, 1.5 mM MgCl2
and 0.25 μMof each primer (Metabion, Martinsried, Germany).
The primer sequences are presented in Table 2. PCR amplifica-
tions were conducted in DNA Engine thermal cycler (Bio-Rad
Laboratories, Hercules, CA, USA). Thermal cycling conditions
were as follows: initial denaturation step at 95 °C for 5 min,
32 cycles at 95 °C for 30 s, 30 s at 63 °C annealing temperature
and 60 s at 72 °C for the SENP1 gene polymorphism, and were
as follows: initial denaturation step at 95 °C for 5 min, 30 cycles
at 95 °C for 30 s, 30 s at 55 °C annealing temperature and 60 s at
72 °C for the SENP2 gene polymorphism.
The products of the c.1691 + 36C > T and c.902C > A
polymorphisms were digested overnight at 37 °C with 0.2 U
of the restriction enzyme EcoRV and PshAI (NEB New
England Biolabs, Ipswich, MA, USA), respectively. The
PCR products were separated into 8 % polyacrylamide gel,
stained with ethidium bromide and viewed under UV light.
Statistical Analysis
Statistical analysis was performed using STATISTICA 8.0
package (Statsoft, Tulsa, OK, USA). Distributions of genotypes
and alleles between groups were tested using the χ2 analysis.
The Hardy-Weinberg equilibriumwas checked using the χ2 test
to compare the observed genotype frequencies with the expect-
ed frequencies among the case and control subjects. For each
SNP, the odds ratios (ORs) and 95 % confidence intervals (CIs)
were calculated. A linkage between genotype, cancer and clin-
ical parameters was assessed by the logistic regression.
Results
Genotype Analysis
Breast cancer patients and controls were divided into groups
corresponding to three genotypes. The distribution of geno-
types of polymorphic variants of the SENP1 and SENP2 genes
for cancer patients and controls is shown in Table 3. The geno-
type distributions for the c.1691 + 36C > T of the SENP1 gene
and c.902C > A of the gene SENP2were not in agreement with
those predicted by the Hardy-Weinberg equilibrium (p < 0.05),
Table 1 The clinical characteristics of breast cancer patients
Characteristic Number of patients
Age
Range: 32–92 324






















Table 2 Primer sequences of the c.1691 + 36C > T polymorphism of
the SENP1 gene (rs12297820) and c.902C > A polymorphism of the
SENP2 gene (rs6762208)
Gene/Polymorphism Primer sequences
SENP1 gene/c.1691 + 36C > T (rs12297820)
Sense 5′-AAGTCTGGCAAAAGGTTCCA -3′
Antisense 5′-TTGCTCCCATTAGGGCATAC-3′
SENP2 gene/c.902C > A (rs6762208)
Sense 5′-CAGAAAAGTTCGTTGACTCCTG-3′
Antisense 5′-CATGGGCACCAAAACATAAG-3′
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except for that of the c.1691 + 36C > T polymorphism of the
SENP1 gene for the patients group. In the case of the SENP1
gene polymorphism we did not find any association between
this polymorphism and breast cancer risk. In the case of SENP2
gene polymorphism we observed higher risk of breast cancer
for carriers of the A allele (OR =1.33; 95 % CI 1.04–1.69). Our
analysis also showed the genotype C/C (OR =0.67, 95 % CI
0.48–0.93) and the allele C (OR =0.75, 95 % CI 0.59–0.69) of
this polymorphism decrease a risk of breast cancer. Figure 1
presents a representative gels from analysis of the c.1691 +
36C > T polymorphism of the SENP1 gene (A) and the
c.902C > A polymorphism of the SENP2 gene (B).
Clinical Parameters of Breast Cancer Patients and SENP1
and SENP2 Genes Polymorphism
We checked the distribution of genotypes and frequency of al-
leles of the SENP1 and SENP2 genes polymorphisms in groups
of patients with different hormone receptor status, patients with
positive and negative lymph node status and patients with
different tumor grade. Odds ratio analysis showed a higher risk
of metastases in women with the genotype C/C (OR =2.07,
95 % CI 1.06–4.05) and allele C (OR =2.10 95 % CI 1.10–
4.01) of the c.1691 + 36C > T SENP1 gene polymorphism
(Table 4). Moreover, we observed reduced risk of metastases
in women with the allele T (OR =0.48, 95 % CI 0.25–0.91) in
this polymorphic site. In the case of SENP2 gene polymorphism
we observed that the A/A genotype correlated with the lack of
estrogen receptor (OR =1.94, 95 % CI 1.04–3.62) (Table 5).
We did not observe any association between: progesterone
receptor status, HER2 expression and tumor grade described
by Bloom-Richardson grading system, and the distribution of
genotypes and frequency of alleles for these polymorphisms
of the SENP1 and SENP2 genes (data not shown).
Discussion
In the present study we correlated the genetic constitution of
breast cancer patients expressed by polymorphic variants of
Table 3 The genotype and allele
frequency and odds ratios (OR) of
the c.1691+ 36C > T
polymorphism of the SENP1 gene
(rs12297820) and the c.902C > A
polymorphism of the SENP2 gene
(rs6762208) in breast cancer
patients and controls
Genotype or allele Breast cancer patients (n = 324) Controls (n = 335) OR (95 % Cl) p
Number Frequency Number Frequency
SENP1 gene/c.1691 + 36C > T (rs12297820)
C/C 253 0.78 257 0.77 1.08 (0.75–1.56) 0.674
C/T 65 0.20 67 0.20 1.00 (0.69–1.47) 0.984
T/T 6 0.02 11 0.03 0.56 (0.20–1.52) 0.253
C 571 0.88 581 0.87 1.12 (0.82–1.54) 0.463
T 77 0.12 89 0.13 0.89 (0.65–1.22) 0.463
SENP2 gene/c.902C > A (rs6762208)
C/C 82 0.25 113 0.34 0.67 (0.48–0.93) ↓ 0.018
C/A 191 0.59 180 0.54 1.24 (0.91–1.68) 0.177
A/A 51 0.16 42 0.12 1.30 (0.84–2.02) 0.239
C 355 0.55 406 0.61 0.75 (0.59–0.96) ↓ 0.021
A 293 0.45 264 0.39 1.33 (1.04–1.69) ↑ 0.021
Data in boldface are statistically significant
a b 
Fig. 1 Genotypes of the of the c.1691 + 36C > T polymorphism of the
SENP1 gene (rs12297820) (a) and c.902C > A (p.Thr301Lys)
polymorphism of the SENP2 gene (rs6762208) (b) analyzed by 8 %
polyacrylamide gel electrophoresis stained with ethidium bromide and
viewed under UV light. Lane M shows GeneRuler TM 100 bp
molecular weight marker
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two SUMO-specific cysteine proteases − SENP1 and SENP2,
with clinical parameters of patients, including lymph node
status, tumor grade, hormone receptors (estrogen and proges-
terone receptors) and epidermal growth factor receptor 2
(HER2) expressions. The c.1691 + 36C > T gene polymor-
phism (rs12297820) is located in the intron region of SENP1
gene. We did not observe any correlation between this poly-
morphism and breast cancer risk (Table 3). However, we
found a higher risk of metastases in women with the genotype
C/C (OR =2.07, 95 % CI 1.06–4.05) and allele C (OR =2.10
95 % CI 1.10–4.01) in this polymorphic site (Table 4.).
Moreover, we observed reduced risk of metastases in women
with the allele T (OR =0.48, 95 % CI 0.25–0.91) (Table 4.).
Our study for the first time showed a link between the vari-
ability of SENP1 gene and metastasis in breast cancer. SENP1
was shown to have a pro-oncogenic role in many types of
cancer. Clinical data showed that SENP1 was positively asso-
ciated with lymph node metastasis and TNM stage pancreatic
ductal adenocarcinoma (PDAC) [12]. Furthermore, knock-
down of SENP1 by SENP1-siRNA inhibited pancreatic can-
cer cell proliferation, migration, and invasion, suggesting that
SENP1 played an important role in PDAC progression and
metastasis. Silencing of SENP1 results in down regulation of
MMP-9, which is pivotal for PDAC cells growth and migra-
tion [12]. SENP1 can also transform normal prostate epithelia
to a dysplastic state and directly modulate several oncogenic
pathways in prostate cells, including AR, c-Jun, and Cyclin
D1 [2, 10]. Assessment of tissue from human prostate cancer
patients indicates elevated mRNA levels of SENP1 and the
SUMO2/3 deconjugating enzyme, SENP3. The induction of
SENP3 in cancer cells initiates the angiogenic pathway; spe-
cifically SENP3 regulates the transcriptional activity of
hypoxia-inducible factor 1α (HIF1α) via desumoylation of
the co-regulatory protein p300. Unlike prostate cancer, en-
hanced sumoylation is favored with onset of breast cancer
and correlated with the reduced SENP6 mRNA levels found
in several breast cancer tissue arrays. Preventing enhanced
SUMO conjugation of cellular substrates in breast cancer cells
reduces tumorigenesis [2].
Latest studies demonstrated that low expression of miR-
145 was correlated with high expression of SENP1 in prostate
cancer cell line PC-3 [11]. The transient introduction of miR-
145 caused cell cycle arrest in PC-3 cells, and the opposite
effect was observed when miR-145 inhibitor was transfected.
Further studies revealed that the SENP1 3′-untranslated region
was a regulative target of miR-145 in vitro. MicroRNA-145
also suppressed tumor formation in vivo in nude mice [11].
Silencing SENP1 level in highly metastatic prostate cancer
cells perturbs their ability to metastasize to the bone and initi-
ates secondary tumors. The expression of two critical bone
remodeling proteins, matrix metalloproteinase 2 (MMP2)
and MMP9, is regulated by SENP1 through the HIF1α sig-
naling pathway. All these results show the contribution of
SENP1 to the progression of prostate cancer, and suggest that
SENP1 may be a prognostic marker and a therapeutic target
for metastasis in prostate cancer patients [11, 13].
In the case of the SENP2 gene polymorphism - c.902C >A,
p.Thr301Lys (rs6762208), we observed correlation between
this site and breast cancer risk (Table 3).Moreover, we noticed
that the A/A genotype correlated with the lack of estrogen
Table 4 The genotype and allele
frequency and odds ratios (OR) of
the c.1691 + 36C > T
polymorphism of the SENP1 gene
(rs12297820) in groups of
patients with breast cancer with
positive and negative lymph node
status
Genotype or allele Node positive (n = 102) Node negative (n = 133) OR (95 % Cl) p
Number Frequency Number Frequency
C/C 87 0.85 98 0.737 2.07 (1.06–4.05)↑ 0033
C/T 15 0.15 33 0.248 0.52 (0.27–1.03) 0059
T/T 0 0 2 0.015 - 0.992
C 189 0.93 229 0.86 2.10 (1.10–4.01)↑ 0.024
T 15 0.07 37 0.14 0.48 (0.25–0.91)↓ 0.024
Data in boldface are statistically significant
Table 5 The genotype and allele
distribution and odds ratios (OR)
of the c.902C > A polymorphism
of the SENP2 gene (rs6762208) in
groups of patients with different
estrogen receptor (ER) status
Genotype or allele ER negative (n = 88) ER positive (n = 235) OR (95 % Cl) p
Number Frequency Number Frequency
C/C 19 0.21 63 0.27 0.75 (0.42–1.35) 0.338
C/A 49 0.56 141 0.60 0.84 (0.51–1.37) 0.483
A/A 20 0.23 31 0.13 1.94 (1.04–3.62) ↑ 0.006
C 87 0.49 267 0.57 0.69 (0.47–1.02) 0.064
A 89 0.51 203 0.43 1.45 (0.98–2.14) 0.014
Data in boldface are statistically significant
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receptor (OR =1.94, 95 % CI 1.04–3.62) (Table 5.) Recently,
it was found that SENP2 significantly repress estradiol-
induced transcriptional activity in breast cancer cells (MCF-
7 and T47D) [17]. It was also demonstrated that ERα repres-
sion by SENP2 is independent of its SUMO protease activity
and requires a transcriptional repressive domain located in the
amino-terminal end of the protease. This domain recruits the
histone deacetylase, HDAC3 to be fully active. Furthermore,
SENP2 robustly repressed estrogen-dependent and indepen-
dent proliferation of MCF-7 cell, and this effect required both
the proteolytic and transcriptional activities of SENP2. The
data identifies SENP2 as a classical transcription co-
regulatory [17].
Goeres et al. (2011) demonstrated that SENP2, although
concentrated at the nuclear basket, is dynamically associated
with nuclear pore complexes (NPCs) [18]. This association is
mediated by multiple targeting elements within the N-
terminus of SENP2 that function cooperatively to mediate
NPC localization. Previously, it was also shown that SENP2
associates with the nuclear face of nuclear pores and that this
association requires protein sequences near the N terminus of
SENP2 [19]. The changes in pore organization and function
observed after depletion of SENP1 and SENP2 indicate that
these proteases contribute to nuclear transport, perhaps by
controlling the configuration of nuclear pore complexes or
modulating the interactions that can take place with pore com-
ponents to promote particular types of traffic [20]. It is also
possible that particular components of the soluble transport
machinery (via their SUMO status) are functionally modulat-
ed by these enzymes, affecting the kinetics of transport for
particular cargo. Overall the pore-associated SUMO proteases
contribute to the fidelity of nuclear pore assembly and the
robustness of nuclear import, suggesting an important means
of contributing to cellular fitness [20].
SENP2 shuttles between the nucleus and the cytoplasm
through an NLS (nuclear localization signal) identified at res-
idues 29 to 49 and an NES (nuclear export signal) at residues
317 to 332 [4]. An autonomous NES localizes in the non-
conserved central domain of the protein that functions through
the CRM1 (Chromosome Region Maintenance 1/exportin1/
Exp1/Xpo1)-dependent nuclear export pathway. Studied by
us polymorphic site in SENP2 gene - c.902C > A,
p.Thr301Lys is located near the NES sequence. The observed
at this point substitutions of amino acids may affect the activ-
ity and substrate specificity of SENP2 as well as
nucleocytoplasmic traffic.
SUMO proteases could represent a group of new targets for
therapeutic intervention in certain human diseases, including
cancer, for which studies have suggested that altered
sumoylation may contribute to both the onset and progression
of the disease [4]. Consequently, in recent years, considerable
progress has been made towards the identification of various
SENP isoforms inhibitors such as protein-based, peptidyl and
small molecule inhibitors [21]. Detailed studies are needed to
clarify therapeutic potential these inhibitors.
Conclusion
The variability of the SENP1 and SENP2 genes may play a
role in breast cancer occurrence. Probably, the examined poly-
morphisms of the SENP1 (c.1691 + 36C > T, rs12297820) and
SENP2 (c.902C > A, p.Thr301Lys, rs6762208) genes cannot
be independent markers of breast cancer but our studies may
be useful in building a set of molecular and clinical markers
helpful for diagnosis and treatment of breast cancer.
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